Manageable safety profile with early efficacy of Tec-DR in NDMM

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant breast cancer

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-positive mCRPC

Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with NDMM: MRD analysis

Melanoma outcomes improved by dual immunotherapy before surgery rather than after

Addition of cabazitaxel to abiraterone/prednisone significantly prolonged PFS in extensive mCRPC following docetaxel

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer

Some advanced epithelial ovarian cancer patients can avoid a lymphadenectomy without impacting survival outcomes

Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma

Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple myeloma